Office Of New Drugs' Oversight Creates Advisory Committee Bias – FDA’s Graham
This article was originally published in The Pink Sheet Daily
Executive Summary
OND’s role in appointing advisory committee members and deciding what issues receive attention leads to a “pro-drug bias and regulatory conflicts of interest,” Office of Drug Safety’s Graham says. FDA “whistleblower” also criticizes disclosure policies for advisory committee members.